// STATE LEGISLATION TRACKER

Florida SB 902: Department of Health

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: Florida
Bill: SB 902
Session: 2026
Filed: 2025-12-15
Read the bill: OpenStates →
Last reviewed: 2026-10-05

Plain-English Summary

Florida SB902 is a broad Department of Health bill, but its listed topics do not point to peptide-specific rules. Based on the title, subjects, and status provided, it does not appear to change compounded peptides, off-label prescribing, telehealth access, NP/naturopath scope, FDA 503A/503B compounding, or PDMP rules for peptide users.

Key Points

No clear peptide-compounding provisions are indicated
No stated change to off-label prescribing or telehealth
No stated change to NP or naturopath peptide practice
Controlled-substance language appears unrelated to peptides
Peptide patients likely see no direct access change

What to Watch For

Note Because this is a broad DOH bill, confirm final chapter text before assuming no pharmacy or prescriber language was added.

Note The controlled-substance item should be checked for scope, but it appears tied to home care for medically fragile children.

Note Medical marijuana changes are health-regulatory but not peptide-specific.

Where the Bill Stands

SB902 was laid on the table after a companion bill passed and became Chapter 2026-59.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws